Anika Therapeutics, Inc. Finance Lease, Principal Payments
Anika Therapeutics, Inc. (ANIK) reported Finance Lease, Principal Payments of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-17.
Financial Statements › Cash Flow › Financing Activities
us-gaap:FinanceLeasePrincipalPayments · last filed 2025-03-17
- Anika Therapeutics, Inc. finance lease, principal payments for the quarter ending 2023-12-31 was $0.00.
- Anika Therapeutics, Inc. finance lease, principal payments for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Anika Therapeutics, Inc. finance lease, principal payments for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- Anika Therapeutics, Inc. finance lease, principal payments for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- Anika Therapeutics, Inc. finance lease, principal payments for fiscal 2024 was $0.00.
- Anika Therapeutics, Inc. finance lease, principal payments for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Anika Therapeutics, Inc. finance lease, principal payments for fiscal 2022 was $284.00K, a 41.29% increase from fiscal 2021.
- Anika Therapeutics, Inc. finance lease, principal payments for fiscal 2021 was $201.00K, a 3.37% decline from fiscal 2020.
| Period end | Finance Lease, Principal Payments 3 month | Finance Lease, Principal Payments 6 month | Finance Lease, Principal Payments 9 month | Finance Lease, Principal Payments 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-17 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $0.00 derived: sum of 2 quarters · filed 2025-03-17 | $0.00 derived: sum of 3 quarters · filed 2025-03-17 | $0.00 10-K · filed 2025-03-17 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $0.00 derived: sum of 2 quarters · filed 2023-11-03 | $0.00 10-Q · filed 2023-11-03 | $0.00 derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | $0.00 derived: sum of 3 quarters · filed 2025-03-17 | $231.00K derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-09 | $0.00 derived: sum of 2 quarters · filed 2025-03-17 | $231.00K derived: sum of 3 quarters · filed 2025-03-17 | $253.00K derived: sum of 4 quarters · filed 2025-03-17 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $231.00K derived: sum of 2 quarters · filed 2025-03-17 | $253.00K derived: sum of 3 quarters · filed 2025-03-17 | $284.00K 10-K · filed 2025-03-17 |
| 2022-09-30 | $231.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $253.00K derived: sum of 2 quarters · filed 2023-11-03 | $284.00K 10-Q · filed 2023-11-03 | $275.00K derived: sum of 4 quarters · filed 2024-03-15 |
| 2022-06-30 | $22.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $53.00K 10-Q · filed 2023-08-08 | $44.00K derived: sum of 3 quarters · filed 2024-03-15 | $107.00K derived: sum of 4 quarters · filed 2024-03-15 |
| 2022-03-31 | $31.00K 10-Q · filed 2023-05-09 | $22.00K derived: sum of 2 quarters · filed 2024-03-15 | $85.00K derived: sum of 3 quarters · filed 2024-03-15 | $113.00K derived: sum of 4 quarters · filed 2024-03-15 |
| 2021-12-31 | -$9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $54.00K derived: sum of 2 quarters · filed 2024-03-15 | $82.00K derived: sum of 3 quarters · filed 2024-03-15 | $201.00K 10-K · filed 2024-03-15 |
| 2021-09-30 | $63.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $91.00K derived: sum of 2 quarters · filed 2022-11-09 | $210.00K 10-Q · filed 2022-11-09 | $263.00K derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-06-30 | $28.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $147.00K 10-Q · filed 2022-08-04 | $200.00K derived: sum of 3 quarters · filed 2023-03-16 | $355.00K derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-03-31 | $119.00K 10-Q · filed 2022-05-06 | $172.00K derived: sum of 2 quarters · filed 2023-03-16 | $327.00K derived: sum of 3 quarters · filed 2023-03-16 | $327.00K derived: sum of 4 quarters · filed 2023-03-16 |
| 2020-12-31 | $53.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $208.00K derived: sum of 2 quarters · filed 2023-03-16 | $208.00K derived: sum of 3 quarters · filed 2023-03-16 | $208.00K 10-K · filed 2023-03-16 |
| 2020-09-30 | $155.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $155.00K derived: sum of 2 quarters · filed 2021-11-05 | $155.00K 10-Q · filed 2021-11-05 | $155.00K derived: sum of 4 quarters · filed 2022-03-11 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $0.00 10-Q · filed 2021-08-06 | $0.00 derived: sum of 3 quarters · filed 2022-03-11 | |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-07 | $0.00 derived: sum of 2 quarters · filed 2022-03-11 | ||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $0.00 10-K · filed 2022-03-11 | ||
| 2019-09-30 | $0.00 10-Q · filed 2020-11-05 | |||
| 2018-12-31 | $0.00 10-K/A · filed 2021-04-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |